**Author's response to reviews**

**Title:** Results of Paclitaxel (day 1 and 8) and Carboplatin Given on Every 3 Weeks in Advanced (stage III-IV) Non-Small Cell Lung Cancer

**Authors:**

Perran F Yumuk (fuldenyumuk@superonline.com)
Nazim S Turhal (turhal@superonline.com)
Mahmut Gumus (mgumus@superonline.com)
Nilgun F Hatabay (fuldenyumuk@superonline.com)
Orhan Turken (oturken@hotmail.com)
Alper Ozkan (mgumus@superonline.com)
Taflan Salepci (tsalepci@hotmail.com)
Mehmet Aliустaoglu (smaliустaoglu@superonline.com)
Rengin Ahiskali (fuldenyumuk@superonline.com)

**Version:** 4 **Date:** 9 November 2004

**Author's response to reviews:**

9 November 2004

Dear Editor,

Thank you very much for considering the manuscript entitled 'Results of Paclitaxel (day 1 and 8) and Carboplatin Given on Every Three Weeks in Advanced (stage III-IV) Non-Small Cell Lung Cancer' for publication in 'BMC Cancer'. I have made all the revisions recommended by the reviewer. These are listed below:

**Major Compulsory Revisions:**
1. How the patients were selected for this study was described in details in the first paragraph of the 'Method' section. Exclusion criteria was also added at the end of this paragraph.
2. The treatment stopping rule was added to the fourth paragraph of the 'Method' section.
3. The treatment continuation rule was added to the forth paragraph of the 'Method' section.
4. 'Conclusion' section of the abstract and the manuscript was corrected as the reviewers' recommendation.
5. Correction was made on the page 10, line 12 and 'better' was replaced by 'more effective'.

**Minor Essential Revisions:**
1. 'Eligible patients' were described in the abstract in detail.
2. All the terms 'three weekly regimen' were changed to 'a regimen given every three weeks' in the manuscript.
3. On page 9, line 15, 'dose' was changed to 'doses'.
4. In table 3 the typo had been corrected.
5. Table 4 was corrected.

**Other Revisions:**
1. Language corrections were made.
2. There was a typo in one of the authors last name and this was corrected as 'Ozkan'.
3. 'Discussion' section, seventh paragraph, the sentence which starts with 'Belani reported...' was changed as 'Belani reported 3-13% of grade 3 or 4 neuropathy, but the incidence was lower for arms 1 (P given weekly and C every four weeks) and 2 (P and C both given weekly), at only 5% and 3%, respectively [21]. This result for arm 1 is similar to the neuropathy rate in our study.' in order to present a clearer data.

I am looking forward to hear your final decision about our manuscript.

Best regards,

Perran Fulden Yumuk, MD